title: Diminished expression of CD59 on activated CD8+ T cells undergoing apoptosis in systemic lupus erythematosus and Sjögren's syndrome.
abstract: The present study was undertaken to examine the phenotype of T cells undergoing in vitro apoptosis in patients with autoimmune diseases such as systemic lupus erythematosus (SLE) and primary Sjögren's syndrome (SS). Compared with normal controls, we found diminished expression of CD59 antigen (one of the cell-surface complement-regulatory proteins) on CD8+ T cells, but not on CD4+ T cells, from patients with SLE and SS. Three-colour immunofluorescence analysis revealed that these CD59dim CD8+ T cells were activated T cells, expressing both human leucocyte antigen (HLA)-DR and CD45RO antigens. In addition, these CD59dim CD8+ T cells were more susceptible to in vitro apoptosis than CD59bright CD8+ T cells. In two patients with active lupus, the percentage of CD59dim CD8+ T cells was significantly decreased after steroid therapy. These findings suggest that decreased expression of CD59 antigen on in vivo-activated CD8+ T cells may be correlated with disease activity and may be involved in activation-induced apoptosis in patients with SLE and SS.
authors.affiliation: Second Department of Internal Medicine; Department of Pediatrics, School of Medicine, Kanazawa University, Kanazawa, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Tsunoda
authors.forename: M
authors.initials: M
authors.lastname: Kawano
authors.forename: I
authors.initials: I
authors.lastname: Koni
authors.forename: Y
authors.initials: Y
authors.lastname: Kasahara
authors.forename: A
authors.initials: A
authors.lastname: Yachie
authors.forename: T
authors.initials: T
authors.lastname: Miyawaki
authors.forename: H
authors.initials: H
authors.lastname: Seki
mesh_terms: D017209:Apoptosis / Q000276:immunology*; D018957:CD59 Antigens / Q000096:biosynthesis*; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology* / Q000378:metabolism* / Q000473:pathology; D002478:Cells, Cultured; D015536:Down-Regulation / Q000276:immunology*; D006801:Humans; D007113:Immunity, Innate; D016130:Immunophenotyping; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy / Q000276:immunology* / Q000473:pathology; D008213:Lymphocyte Activation; D018655:Lymphocyte Count; D011239:Prednisolone / Q000008:administration & dosage; D020551:Pulse Therapy, Drug; D012859:Sjogren's Syndrome / Q000276:immunology* / Q000473:pathology; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000378:metabolism / Q000473:pathology
chemical_list: D018957:CD59 Antigens; D011239:Prednisolone